SCHEMBL848159

SCHEMBL848159

COc1c(-c2cc3ccccc3c(=O)[nH]2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.47
TNKS O95271 4/20 0.39
KDM4E B2RXH2 4/20 0.35
GAA P10253 2/20 0.35
ALDH1A1 P00352 3/20 0.35
HPGD P15428 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
CDC25B P30305 3/20 0.35
THRB P10828 1/20 0.35
PDGFRB P09619 2/20 0.35
EGFR P00533 1/20 0.34
ERBB2 P04626 1/20 0.34
APAF1 O14727 1/20 0.33
TDP2 O95551 1/20 0.33
CASP3 P42574 1/20 0.33
CASP7 P55210 1/20 0.33
CASP9 P55211 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3405437 0.84 CYP3A4 (0.61) CYP3A4
SCHEMBL860732 0.82 PTGES (0.48) CYP3A4KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL13071134 0.78 TNKS (0.41) TNKSKDM4EALDH1A1HPGDRAB9A
SCHEMBL13030240 0.78 ALDH1A1 (0.38) CYP3A4TNKSKDM4EALDH1A1HPGD
SCHEMBL1543040 0.77 CYP3A4 (0.55) CYP3A4KDM4EGAAALDH1A1HPGD
SCHEMBL1542685 0.77 CYP3A4 (0.55) CYP3A4PDGFRBEGFRERBB2
SCHEMBL2128598 0.76 CYP3A4 (0.54) CYP3A4ALDH1A1THRBPDGFRBEGFR
SCHEMBL2128925 0.76 CYP3A4 (0.54) CYP3A4KDM4EGAAALDH1A1RAB9A
SCHEMBL1542385 0.74 CYP3A4 (0.64) CYP3A4KDM4EGAAALDH1A1RAB9A
SCHEMBL2128919 0.73 CYP3A4 (0.52) CYP3A4EGFRERBB2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2432554-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-03-28 EP claimed
WO-2010133528-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-25 WO claimed
US-20100297073-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS CHIN ELBERT 2010-11-25 US claimed
US-20100297073-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS CHIN ELBERT 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297073-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B CYP3A4 302/4885TNKS 1898/4885KDM4E 1388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.